New vitamin b shot with energy booster aims to soothe diabetic nerve pain
NCT ID NCT07296354
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an injectable supplement that combines B vitamins with an energy molecule (ATP) to treat painful diabetic nerve damage. Two hundred adults with diabetes and nerve pain will receive either the ATP-enhanced shot or a standard B vitamin shot for 12 weeks. Researchers will measure changes in nerve pain symptoms and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ATP-containing vitamin B complex injection (Epinosine B Forte)
What this could lead to
If it works, this could offer a new option to ease nerve pain and improve quality of life for people with diabetic neuropathy.
What could go wrong
This is a phase 4 trial, but it hasn't started yet. The benefit over standard B vitamins may be small, and side effects like injection site reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROPATHIC PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••